首页> 外文学位 >The impact of cardiovascular disease risk factors and treatments on the development of gout.
【24h】

The impact of cardiovascular disease risk factors and treatments on the development of gout.

机译:心血管疾病危险因素和治疗方法对痛风发展的影响。

获取原文
获取原文并翻译 | 示例

摘要

Objective. The goal of this dissertation is to fill the knowledge gap of the role of obesity, hypertension, diuretic use, and urate genes on the development of gout.;Methods. This dissertation utilized two longitudinal cohorts: CLUE and ARIC. Incident gout was the outcome of interest. The association of obesity and gout was estimated using a Poisson regression for cumulative incidence ratios (RR). Multivariate Cox Proportional analysis estimated the Hazard Rate Ratio (HR) to test the association of gout with hypertension and diuretic use (among hypertensive participants). The gene-by-diuretic interaction was tested using a logistic regression model and estimated Odds Ratios (OR). We tested the direct effect of urate genes on gout after accounting for biological variability in serum urate using a Cox Proportional model with regression calibration. All models were adjusted for confounders.;Results. Self-reported gout status was reliable (kappa=0.73) and sensitive (84%). The 18-year RR of gout in obese participants compared to non-obese participants was 1.92 (95% Confidence Interval (CI): 1.55, 2.37); the onset of gout was 3.1 years (95% CI: 0.3, 5.8) earlier in those who were obese at baseline and 11.0 years earlier (95% CI: 5.8, 16.1) in those obese at age 21. Hypertension (HR= 2.18; 95% CI: 1.68, 2.83), diuretic use (HR=1.48, 95% CI: 1.11, 1.98), thiazide diuretic use (HR=1.44, 95% CI: 1.00, 2.10), and loop diuretic use (HR=2.31, 95% CI: 1.36, 3.91) were all associated with gout. Serum urate mediated these associations. Use of a thiazide or loop diuretic was associated with gout for those with a genetic score above the median, OR 2.18 (95% CI: 1.31, 3.64) but not among those with a genetic mate score below the median, OR 0.37 (95% CI: 0.13, 1.03); p-value for interaction=0.003. Finally, the association of urate genes with incident gout was almost completely explained by serum urate level once long term variation was taken into account (HR=6.50, 95% CI: 2.69, 15.70 dropped to 2.45; 95% CI: 0.96, 6.22; p-value=0.06), suggesting full mediation by serum urate level.;Conclusions. This dissertation confirms and extends the association of known gout risk factors, obesity, hypertension, and diuretic use. We identified novel subpopulations at increased gout risk due to genetic and environmental exposures.
机译:目的。本文的目的是填补肥胖,高血压,利尿剂使用和尿酸基因在痛风发展中的作用的知识空白。本文利用两个纵向队列:CLUE和ARIC。痛风是人们关注的结果。肥胖和痛风之间的关联使用累积发病率(RR)的Poisson回归进行估算。多变量Cox比例分析估计了危险率(HR),以测试痛风与高血压和利尿剂的使用(在高血压参与者中)。使用逻辑回归模型和估计的赔率(OR)对基因与利尿剂之间的相互作用进行了测试。在使用回归校准的Cox比例模型考虑了血清尿酸盐的生物学变异性之后,我们测试了尿酸盐基因对痛风的直接影响。所有模型都针对混杂因素进行了调整。自我报告的痛风状态可靠(kappa = 0.73),敏感(84%)。肥胖参与者与非肥胖参与者相比,痛风的18年RR为1.92(95%置信区间(CI):1.55、2.37);基线肥胖者的痛风发作时间提前了3.1年(95%CI:0.3,5.8),而21岁肥胖者的痛风发作提前了11.0年(95%CI:5.8,16.1)。高血压(HR = 2.18; 95%CI:1.68,2.83),利尿剂使用(HR = 1.48、95%CI:1.11、1.98),噻嗪类利尿剂使用(HR = 1.44、95%CI:1.00、2.10)和loop利尿剂使用(HR = 2.31) ,95%CI:1.36、3.91)均与痛风有关。血清尿酸盐介导了这些关联。遗传评分高于中位数OR 2.18(95%CI:1.31、3.64)的患者,使用噻嗪类或loop利尿剂与痛风相关,但遗传伴侣评分低于中位数OR 0.37(95%)的患者与痛风相关CI:0.13,1.03);互动的p值= 0.003。最后,一旦考虑到长期变化,尿酸盐基因与入射痛风的关联几乎完全由血清尿酸盐水平来解释(HR = 6.50,95%CI:2.69,15.70降至2.45; 95%CI:0.96,6.22; p-值= 0.06),表明完全由血清尿酸水平介导。本论文证实并扩展了已知痛风危险因素,肥胖,高血压和利尿剂使用的关联。我们确定了由于遗传和环境暴露而导致痛风风险增加的新型亚群。

著录项

  • 作者

    McAdams DeMarco, Mara Ann.;

  • 作者单位

    The Johns Hopkins University.;

  • 授予单位 The Johns Hopkins University.;
  • 学科 Health Sciences Epidemiology.
  • 学位 Ph.D.
  • 年度 2011
  • 页码 149 p.
  • 总页数 149
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:44:06

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号